Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models.
The future of nucleic acid-based therapeutics is dependent on achieving successful delivery. Recently, there has been an increasing interest in delivery via the gastrointestinal tract. Gene therapy via this route has many advantages, including non-invasive access and the versatility to treat local diseases, such as inflammatory bowel disease, as well as systemic diseases, such as haemophilia. However, the intestine presents several distinct barriers and, therefore, the design of robust non-viral delivery systems is key to future success. Several non-viral delivery strategies have provided evidence of activity in vivo. To facilitate the design of more efficient and safe gene medicines, more physiologically relevant models, at both the in vitro and in vivo levels, are essential.
Pharmacodelivery Group, School of Pharmacy, University College Cork, Ireland.
Martin J
MJ
O'Neill
Ludovic
L
Bourre
Silvia
S
Melgar
Caitriona M
CM
O'Driscoll
D000818:Animals; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*